Geneology International

Tag: cannabinoids

  • THC vs. CBD: Comparing The Most Popular Cannabinoids – Boca Raton’s Most Reliable News Source

    THC vs. CBD: Comparing The Most Popular Cannabinoids – Boca Raton’s Most Reliable News Source

    CBD THC
    Definition A non-psychoactive compound discovered in hashish The psychoactive compound observed in cannabis
    Consequences May perhaps have a selection of probable health and fitness rewards, including cutting down stress and swelling Can make a sensation of euphoria or “high”
    Legality Legal in most destinations if derived from hemp Illegal in most locations, besides for clinical use

    It’s crucial to note that CBD and THC are just two of the several compounds found in hashish. They are both equally cannabinoids, but they have incredibly distinctive effects on the body and head. CBD is non-psychoactive, indicating it does not generate a high, while THC is the principal psychoactive compound in hashish and is liable for the significant associated with marijuana use.

    CBD has obtained attractiveness in current a long time owing to its prospective wellness advantages, and it is now readily available in a assortment of kinds, such as oils, capsules, and edibles. THC, on the other hand, is however largely involved with recreational cannabis use, while it is also utilized for medicinal uses in some states exactly where cannabis is legal.

    After decades of research, we’ve concluded that THC and CBD are without a doubt really diverse! In spite of their similarity in structure and opportunity benefits, there is a major distinction in chemical composition and interaction with our endocannabinoid receptors. In most experiments, the similar results are shared. THC and CBD do not bind to the exact receptors and interact otherwise.

    As a result, CBD products and solutions are distinct from THC merchandise in terms of how they make you feel. 

    In the health-related neighborhood, cannabidiol (CBD) has received a good deal of attention. Researchers are doing the job on new formulations that might advantage patients with a variety of serious disorders. 

    CBD merchandise are starting to be extra common as additional companies market CBD as a new health and wellness drugs. Study suggests that the blend of THC and CBD has larger therapeutic results on people. 

    Throughout the final couple a long time, solutions these as CBD gummies, cookies, oils, capsules, and creams have taken the sector by storm. Let us master far more about the discrepancies amongst these two cannabinoids:

    Evaluating The Psychoactive Facet Effects

    As a psychoactive compound, THC (tetrahydrocannabinol) impacts your brain by binding to the cannabinoid receptors in your brain and mimicking anandamide, a neurotransmitter liable for regulating temper, sleep patterns, and memory.

    As opposed to THC, CBD does not bind to these receptors, so it does not get you higher. Alternatively, it has anti-inflammatory attributes, assisting with agony reduction and cutting down stress, melancholy, and even psychosis.

    Additionally, THC binds to CB1 receptors in the mind and nervous technique, as perfectly as CB2 receptors in the immune and gastrointestinal methods.

    The CBD molecule does not bind effectively to possibly CB1 or CB2 receptors, so it does not have any mind-altering results. Even so, it does have some anti-inflammatory and anti-anxiety results.

    There are lots of variances in between THC and CBD cannabinoids. For illustration, when both equally can influence us emotionally or mentally, THC may possibly trigger paranoia, whereas CBD does not seem to be to do so. In addition, while equally strains can minimize agony for some men and women, their efficiency varies greatly — this means their effects can modify depending on strain, dosage, and terpene information.

    Comparing The Outcomes on Urge for food

    Cannabis is regarded to maximize appetite and develop inner thoughts of euphoria. This can be beneficial for most cancers individuals who suffer from nausea and loss of hunger. Nonetheless, it can also lead to overeating and weight acquire in users.

    There is no proof that CBD has this effect. Nevertheless, some scientific tests propose that it has anti-inflammatory properties, which may perhaps endorse bodyweight loss and even decrease weight acquire.

    Evaluating The Authorized Status

    The marijuana business is constantly evolving. Even though quite a few states have legalized the leisure use of THC-made up of cannabis, it continues to be unlawful underneath federal legislation. Numerous states nevertheless permit medical cannabis containing THC. When it will come to CBD and other hemp-derived cannabinoids, the lawful status is a tad various

     While CBD is lawful at the federal level, a selection of other cannabinoids have been synthesized from CBD extraction in new a long time. Shopping for hemp-derived merchandise must be investigated in advance of purchasing. Other varieties of THC, this kind of as delta 8, delta 10, and HHC, are authorized in some states but are restricted in other folks.

  • With highly concentrated cannabinoids, BioHarvest takes aim at medical and dietary-supplement markets

    With highly concentrated cannabinoids, BioHarvest takes aim at medical and dietary-supplement markets

    Canadian and Israeli microcap biotech business BioHarvest Sciences Inc. has launched the initially hashish and hemp compositions manufactured through its proprietary bioreactor method.

    BioHarvest
    CNVCF,
    -2.17{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}

    BHSC,
    -7.94{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}
    works by using its bioreactor engineering to refine helpful compounds in hashish into concentrated doses for probable use in medicines and nutritional supplements.

    According to unbiased third-social gathering information cited by the enterprise, BioHarvest has been in a position to boost the percentage of cannabinoids to 36{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}, up from the 3{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} located in the plant, and to enhance the THC stage by 83 instances. It is also ready to boost more rare cannabinoids these kinds of as CBDV and THCV by 88 situations and 249 moments respectively, compared with a sampled hashish plant.

    The process offers the capability to incorporate more substantial doses of CBDV and THCV, which includes what the company says is a “unique” 4-to-1 blend CBD/CBDV isolate that could be “disruptive” in the hemp-centered dietary-supplement market place.

    “This would enable new hemp-based mostly therapeutical products and solutions, together with distillates, at a federally lawful nationwide stage in the U.S.,” BioHarvest mentioned. “The existence of important amounts of all other extra elusive cannabinoids could help deal with ADHD, soreness administration issues, and stress.”

    BioHarvest isolates trichomes, which are the resin-generating glands on hashish and hemp flowers, and grows them in the lab. The procedure offers it the ability to “unlock uncommon cannabinoids not detectable in the plant,” the firm said.

    Also examine: Hashish M&A cools but promotions continue to be on the desk regardless of scuttled Verano acquisition, analyst says

    BioHarvest’s approach is also 54 periods more successful for every gallon of water than indoor hashish cultivation and 8 instances far more successful for electric power when compared with greenhouses, the enterprise explained. It features 19 times much more general manufacturing intensity than indoor cultivation.

    BioHarvest CEO Ilan Sobel said the company’s products and process open the door to “many industrial applications.”

    Chris D’Adamo, assistant professor at University of Maryland School of Medicine who directs the school’s integrative medicine study center, mentioned he’s noticed “considerable success” in patients addressed with CBD for suffering, anxiousness and stress.

    Also go through: Hashish legalization goes up for a vote Nov. 8 in five states with a mixed grownup inhabitants of 13 million

    BioHarvest’s capability to offer you a great deal larger doses of compounds this sort of as THCV and CBDV is desirable, D’Adamo mentioned.

    “What bought me energized was the ability to tailor the CBD,” D’Adamo claimed. “I am incredibly amazed with the way they could escalate the uncommon cannabinoids.”

    D’Adamo mentioned he was familiar with BioHarvest’s Vinia products, a dietary red grape/crimson wine focus that aims to increase cardiovascular well being. The organization is known for getting a sound scientific team, he mentioned.

    Shares of BioHarvest are up 2{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} on Wednesday. The stock is down 34.9{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} in 2022, compared with a 28.8{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} reduction by the Nasdaq. At previous test, the company’s market place capitalization was $107 million.

    Also examine: Bronfman-backed Capsoil provides nano powder tech to hashish with initial edibles line

  • NFL awards million for studies on cannabinoids’ effects on pain management in players

    NFL awards $1 million for studies on cannabinoids’ effects on pain management in players

    The NFL is awarding $1 million in research funding to two teams of clinical scientists to research the outcomes of cannabinoids on discomfort administration and neuroprotection from concussion in elite football gamers.

    Health care groups from the University of California San Diego and College of Regina in Canada ended up picked from 106 proposals initiated by the NFL and the NFL Gamers Association’s Joint Ache Administration Committee in June 2021.

    “We’re normally interested in seeking to make improvements to our method and our procedure for acute and long-term pain in NFL gamers, and we constantly want to make positive that our players are obtaining the most up-to-day medical consensus all around any of these treatment options,” NFL main medical officer Dr. Allen Sills informed The Associated Press. “So, our burden of evidence is actually large for NFL gamers. Whenever we want to introduce a new treatment, we have to fully grasp how that decision may well effect their nicely-currently being and their functionality. We know you will find been a ton of desire in this place, but we did not really feel like there was a large amount of excellent reliable investigation on the advantages of cannabis, CBD and managing acute and long-term pain. So, that is why we wished to try out to add to the system of science in this region.”

    Dr. Kevin Hill, the director of addiction psychiatry at Beth Israel Deaconess Health care Center and a preeminent cannabis researcher and writer, is the co-chair of the NFL-NFLPA Joint Suffering Management Committee. Hill discussed why there has not been significantly exploration on this matter.

    “One explanation is the [DEA] scheduling of hashish will make it more challenging to do this study, but the key purpose is that stakeholders truly are not fascinated in advancing the science,” Hill informed the AP. “You have states and firms that are producing a whole lot of income selling cannabis merchandise, selling CBD merchandise proper now. So they don’t experience the need to have to demonstrate the efficacy of these products, and thousands and thousands of people are applying them. So which is the predicament that we are in as health and fitness treatment professionals or organizations that genuinely treatment about the wellbeing and safety of our constituents, the players in this scenario.

    “We genuinely want to know, do they operate? And just about every working day I meet up with with individuals who are interested in cannabinoids, and it really is the very same detail — we truly will not know the answers to that. So it gets to be a quite complex chance/reward dialogue. So I am thrilled to be a element of something that truly is likely to get toward getting some responses to the queries that everybody’s been conversing about for many years.”

    The $1 million investigation grant is a progressive go by the league to improved realize and boost substitute soreness management treatment plans. Many NFL players around the decades have inquired about the gains of hashish and cannabinoids. A number of previous players are involved in the healthcare-cannabis organization and have possibly started off their have makes, invested in corporations or been hired as ambassadors.

    “We have listened to from the teams, from the clinical staffs, from the gamers loud and crystal clear that they are fascinated in hashish and cannabinoids, and so we desired to do anything that would advance the science in this area so that we could have improved informed conversations with them,” Hill mentioned. “I also want to emphasize that this is the initially stage below. The NFL has finished terrific research in other places: concussions, musculoskeletal accidents, and many others. We’re not limited just to cannabinoids. We are interested in figuring out, are there ways that we can deal with pain much better? And so we’re heading to use this and appear at this process and see if you will find a way that we can improve this procedure, but continue on to try to progress the science in the interest of players’ wellbeing and safety.”

    Hashish is a banned substance in the NFL, although policies about gamers using marijuana had been loosened in the most recent collective bargaining settlement.

    Less than the most the latest labor deal, players who examination favourable for marijuana are no lengthier suspended but they can be fined depending on the range of constructive assessments. Timing of screening was altered to the 1st two months of education camp in its place of from April to August. Also, the threshold wanted to cause a beneficial test was elevated fourfold.

    The review led by Dr. Thomas Marcotte, Dr. Mark Wallace and scientists at the College of California San Diego will look into the outcomes of cannabinoids on pain and restoration from athletics-linked accidents in elite athletes.

    The investigate led by Dr. J. Patrick Neary and scientists at the University of Regina scientific tests by natural means developed cannabinoids for discomfort management and neuroprotection from concussion and participation in get hold of athletics.

    The projects will consider three years to conduct.

    “This type of get the job done is going to be of desire to athletes in quite a few distinct sporting activities and at all degrees,” Sills claimed. “We know that all sporting activities have some degree of personal injury and soreness that are related with those people injuries. And so I assume this will be very generalizable. These goods are already out there and in numerous conditions, they are remaining broadly employed and broadly marketed. So this investigate will aid inform folks as to which strategies might be valuable and then those people that may perhaps not be. And so I see this as being hugely impactful for the NFL, for all of the elite sport, but also activity at all degree across society.”

  • Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

    Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

  • 1.

    Park, J. Y. & Wu, L. T. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review. Drug. Alcohol. Depend. 177, 1–13. https://doi.org/10.1016/j.drugalcdep.2017.03.009 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 2.

    Epidyolex|European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (2021).

  • 3.

    Anwar, A., Saleem, S., Patel, U. K., Arumaithurai, K. & Malik, P. Dravet syndrome: An overview. Cureus https://doi.org/10.7759/cureus.5006 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 4.

    Asadi-Pooya, A. A. Lennox-Gastaut syndrome: A comprehensive review. Neurol. Sci. 393(39), 403–414 (2017).


    Google Scholar     

  • 5.

    Swaminath, A. et al. The role of cannabis in the management of inflammatory bowel disease: a review of clinical, scientific, and regulatory informationcommissioned by the crohn’s and colitis foundation. Inflamm. Bowel Dis. 25, 427–435. https://doi.org/10.1093/ibd/izy319 (2019).

    Article 
    PubMed 

    Google Scholar     

  • 6.

    Aran, A., Cassuto, H., Lubotzky, A., Wattad, N. & Hazan, E. Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J. Autism Dev. Disord. 49, 1284–1288. https://doi.org/10.1007/s10803-018-3808-2 (2019).

    Article 
    PubMed 

    Google Scholar     

  • 7.

    Ben-Zeev, B. Medical cannabis for intractable epilepsy in childhood: A review. Rambam Maimonides Med. J. 11, e0004. https://doi.org/10.5041/RMMJ.10387 (2020).

    Article 
    PubMed Central 

    Google Scholar     

  • 8.

    Tramèr, M. R. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. Br. Med. J. 323, 16–21. https://doi.org/10.1136/bmj.323.7303.16 (2001).

    Article 

    Google Scholar     

  • 9.

    Pacher, P., Kogan, N. M. & Mechoulam, R. Beyond THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60, 637–659. https://doi.org/10.1146/annurev-pharmtox-010818-021441 (2020).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 10.

    Skrypek, M. M., Bostrom, B. C. & Bendel, A. E. Medical cannabis certification in a large pediatric oncology center. Children 6, 79. https://doi.org/10.3390/children6060079 (2019).

    Article 
    PubMed Central 

    Google Scholar     

  • 11.

    National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 58,91,97,245 (Washington, DC: The National Academies Press. 2017), DOI: https://doi.org/10.17226/24625.

  • 12.

    Bourgeois, F. T. et al. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 130, 285–292. https://doi.org/10.1542/peds.2012-0139 (2012).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 13.

    Mueller, B. U. et al. Principles of pediatric patient safety: Reducing harm due to medical care. Pediatrics 143, 2. https://doi.org/10.1542/peds.2012-0139 (2019).

    Article 

    Google Scholar     

  • 14.

    Volkow, N. D., Baler, R. D., Compton, W. M. & Weiss, S. R. B. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219–2227. https://doi.org/10.1056/NEJMra1402309 (2014).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 15.

    Kelly, B. F. & Nappe, T. M. Cannabinoid Toxicity. Treasure Island (FL): StatPearls (StatPearls Publishing, 2019). PMID: 29489164.

  • 16.

    Martín-Gómez, A., Palacios-Gómez, M. E. & García-Marcos, S. A. Severe intradialytic hypoglycemia associated with marijuana use. Nefrologia. 35, 328–329. https://doi.org/10.1016/j.nefroe.2015.02.001 (2015).

    Article 
    PubMed 

    Google Scholar     

  • 17.

    Naji, L. et al. The association between cannabis use and suicidal behavior in patients with psychiatric disorders: an analysis of sex differences. Biol. Sex Differ. 9, 22. https://doi.org/10.1186/s13293-018-0182-x (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 18.

    Ragazzi, T. C. C., Shuhama, R., Menezes, P. R. & Del-Ben, C. M. Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. Early Interv. Psychiatry 12, 1013–1023. https://doi.org/10.1111/eip.12693 (2018).

    Article 
    PubMed 

    Google Scholar     

  • 19.

    Lev-Ran, S. et al. The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychol. Med. 44, 797–810. https://doi.org/10.1017/S0033291713001438 (2014).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 20.

    van Gastel, W. A. et al. Change in cannabis use in the general population: A longitudinal study on the impact on psychotic experiences. Schizophr. Res. 157, 266–270. https://doi.org/10.1016/J.SCHRES.2014.04.023 (2014).

    Article 
    PubMed 

    Google Scholar     

  • 21.

    Appelboam, A. & Oades, P. J. Coma due to cannabis toxicity in an infant. Eur. J. Emerg. Med. 13, 177–179. https://doi.org/10.1097/01.mej.0000194405.38206.f2 (2006).

    Article 
    PubMed 

    Google Scholar     

  • 22.

    Carstairs, S. D., Fujinaka, M. K., Keeney, G. E. & Ly, B. T. Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine. J. Emerg. Med. 41, 3. https://doi.org/10.1016/j.jemermed.2010.05.032 (2011).

    Article 

    Google Scholar     

  • 23.

    Bonkowsky, J. L., Sarco, D. & Pomeroy, S. L. Ataxia and shaking in a 2-year-old girl: Acute marijuana intoxication presenting as seizure. Pediatr. Emerg. Care. 21, 527–528. https://doi.org/10.1097/01.pec.0000173349.38024.33 (2005).

    Article 
    PubMed 

    Google Scholar     

  • 24.

    Richards, J. R., Smith, N. E. & Moulin, A. K. Unintentional cannabis ingestion in children: A systematic review. J. Pediatr. 190, 142–152. https://doi.org/10.1016/j.jpeds.2017.07.005 (2017).

    Article 
    PubMed 

    Google Scholar     

  • 25.

    Corsi, D. J. et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat. Med. 26, 1536–1540. https://doi.org/10.1038/s41591-020-1002-5 (2020).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 26.

    Sadhana, D., Kathleen, M. & Jonathan, D. K. Marijuana and the pediatric population. Pediatrics https://doi.org/10.1542/peds.2019-2629 (2020).

    Article 

    Google Scholar     

  • 27.

    Wong, S. S. & Wilens, T. E. Medical cannabinoids in children and adolescents: A systematic review. Pediatrics 140, 5. https://doi.org/10.1542/peds.2017-1818 (2017).

    Article 

    Google Scholar     

  • 28.

    Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N. Engl. J. Med. 376, 2011–2020. https://doi.org/10.1056/NEJMoa1611618 (2017).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 29.

    Porcari, G. S., Fu, C., Doll, E. D., Carter, E. G. & Carson, R. P. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy Behav. 80, 240–246. https://doi.org/10.1016/j.yebeh.2018.01.026 (2018).

    Article 
    PubMed 

    Google Scholar     

  • 30.

    Devinsky, O. et al. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N. Engl. J. Med. 378, 1888–1897. https://doi.org/10.1056/NEJMoa1714631 (2018).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 31.

    Lattanzi, S. et al. Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis. Drugs 78, 1791–1804. https://doi.org/10.1007/s40265-018-0992-5 (2018).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 32.

    de Carvalho, R. R., Almeida, K. J., da Silva, L. L., de Melo Mendes, C. M. & Bor-Seng-Shu, E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 102, 106635. https://doi.org/10.1016/j.yebeh.2019.106635 (2020).

    Article 

    Google Scholar     

  • 33.

    Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700. https://doi.org/10.1136/bmj.b2700 (2009).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 34.

    Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 5(210), 1. https://doi.org/10.1186/s13643-016-0384-4 (2016).

    Article 

    Google Scholar     

  • 35.

    Sterne, J. A. et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919. https://doi.org/10.1136/bmj.i4919 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 36.

    Higgins, J. P. T. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, i7829. https://doi.org/10.1136/bmj.d5928 (2011).

    Article 

    Google Scholar     

  • 37.

    Busner, J. & Targum, S. D. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiat. Edgmont 4(7), 28–37 (2007).


    Google Scholar     

  • 38.

    European Medicines Agency. Important medical event terms list (MedDRA version 23.0, updated). https://www.ema.europa.eu/en/documents/other/important-medical-event-terms-list-version-meddra-version-221_en.xls (2020).

  • 39.

    Viechtbauer, W. Conducting meta-analyses in R with the metafor. J. Stat. Softw. 36, 1–48. https://doi.org/10.18637/jss.v036.i03 (2010).

    Article 

    Google Scholar     

  • 40.

    Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based. Ment. Health 22, 153–160. https://doi.org/10.1136/ebmental-2019-300117 (2019).

    Article 
    PubMed 

    Google Scholar     

  • 41.

    Rücker, G., Krahn, U., König, J., Efthimiou, O. & Schwarzer, G. Package ‘netmeta’ title network meta-analysis using frequentist methods. Epidemiol. Health https://doi.org/10.1007/978-3-319-21416 (2020).

    Article 

    Google Scholar     

  • 42.

    McGrath, S., Zhao, X., Steele, R. & Benedetti, A. Package ‘metamedian’ Title Meta-Analysis of Medians. (2020). https://doi.org/10.1002/sim.8013.

  • 43.

    Copenhagen Trial Unit. Trial Sequential Analysis Viewer. (2016).

  • 44.

    Wetterslev, J., Thorlund, K., Brok, J. & Gluud, C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med. Res. Methodol. 91(9), 1–12. https://doi.org/10.1186/1471-2288-9-86 (2009).

    CAS 
    Article 

    Google Scholar     

  • 45.

    Borenstein, M., Hedges, L., Higgins, J., Rothstein, H. & Biostat Englewood, N.J. Comprehensive Meta-Analysis 3. (2013).

  • 46.

    Dean, A.G., Sullivan, K.M., Soe, M.M. OpenEpi: Open source epidemiologic statistics for public health, Version. www.OpenEpi.com, updated 2013/04/06, accessed 2021/10/16.

  • 47.

    Page, M. J. et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: A cross-sectional study. PLOS Med. 13, e1002028. https://doi.org/10.1371/journal.pmed.1002028 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 48.

    Chan, S. G., Correia, A. J. & MecLeod, M. S. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial. Pediatrics 79(6), 946–952 (1987).

    CAS 
    PubMed 

    Google Scholar     

  • 49.

    Dalzell, A. M., Bartlett, H. & Lilleyman, J. S. Nabilone: An alternative antiemetic for cancer chemotherapy. Arch. Dis. Child. 61, 502–505. https://doi.org/10.1136/adc.61.5.502 (1986).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 50.

    Miller, I. et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: A randomized clinical trial. JAMA Neurol. 77, 613–621. https://doi.org/10.1001/jamaneurol.2020.0073 (2020).

    Article 
    PubMed 

    Google Scholar     

  • 51.

    Fairhurst, C., Kumar, R., Checketts, D., Tayo, B. & Turner, S. Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Dev. Med. Child Neurol. 62, 1031–1039. https://doi.org/10.1111/dmcn.14548 (2020).

    Article 
    PubMed 

    Google Scholar     

  • 52.

    Efron, D. et al. A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability. Br. J. Clin. Pharmacol. 87, 436–446. https://doi.org/10.1111/bcp.14399 (2021).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 53.

    Aran, A. et al. Cannabinoid treatment for autism: A proof-of-concept randomized trial. Mol. Autism 12, 1–11. https://doi.org/10.1186/S13229-021-00420-2 (2021).

    Article 

    Google Scholar     

  • 54.

    Devinsky, O. et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 90, e1204–e1211. https://doi.org/10.1212/WNL.0000000000005254 (2018).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 55.

    Chesney, E. et al. Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45, 1799–1806. https://doi.org/10.1038/s41386-020-0667-2 (2020).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 56.

    Malyshevskaya, O. et al. Natural (∆ 9 -THC) and synthetic (JWH-018) cannabinoids induce seizures by acting through the cannabinoid CB 1 receptor. Sci. Rep. 2017(7), 1–8. https://doi.org/10.1038/s41598-017-10447-2 (2017).

    CAS 
    Article 

    Google Scholar     

  • 57.

    FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms (2018).

  • 58.

    Ruggiero, A. et al. Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment. J. Int. Med. Res. 46, 2149–2156. https://doi.org/10.1177/0300060518765324 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 59.

    NICE. Cannabis-based medicinal products: [A] Evidence review for intractable nausea and vomiting NICE guideline NG144 Evidence review underpinning recommendations 1.1.1 and 1.1.2 in the NICE guideline. (2019).

  • 60.

    Huestis, M. A. et al. Cannabidiol adverse effects and toxicity. Curr. Neuropharmacol. 17, 974–989. https://doi.org/10.2174/1570159×17666190603171901 (2019).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 61.

    Stockings, E. et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J. Neurol. Neurosurg. Psychiat. 89, 741–753. https://doi.org/10.1136/JNNP-2017-317168 (2018).

    Article 
    PubMed 

    Google Scholar     

  • 62.

    Wiley, J. L. et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 145, 293. https://doi.org/10.1038/SJ.BJP.0706157 (2005).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 63.

    Jankowska, B. I., Jankowski, M. M. & Swiergiel, A. H. Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. Neurosci. Lett. 490, 82–84. https://doi.org/10.1016/J.NEULET.2010.12.031 (2011).

    Article 

    Google Scholar     

  • 64.

    Skluzacek, J. V., Watts, K. P., Parsy, O., Wical, B. & Camfield, P. Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 52, 95–101. https://doi.org/10.1111/j.1528-1167.2011.03012.x (2011).

    Article 
    PubMed 

    Google Scholar     

  • 65.

    Bandini, L. G. et al. Changes in food selectivity in children with autism spectrum disorder. J. Autism Dev. Disord. 47, 439–446. https://doi.org/10.1007/s10803-016-2963-6 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 66.

    Di Marzo, V. & Piscitelli, F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics 12, 692. https://doi.org/10.1007/s13311-015-0374-6 (2015).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 67.

    Zou, S. & Kumar, U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. 1, 9. https://doi.org/10.3390/ijms19030833 (2018).

    CAS 
    Article 

    Google Scholar     

  • 68.

    Netzahualcoyotzi, C., Rodríguez-Serrano, L. M., Chávez-Hernández, M. E. & Buenrostro-Jáuregui, M. H. Early consumption of cannabinoids: From adult neurogenesis to behavior. Int. J. Mol. Sci. 22, 7450. https://doi.org/10.3390/ijms22147450 (2021).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 69.

    Solowij, N. et al. Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: A pragmatic open-label clinical trial. Cannabis Cannabinoid. Res. 3, 21–34. https://doi.org/10.1089/can.2017.004 (2018).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • 70.

    Osborne, A. L., Solowij, N. & Weston-Green, K. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Neurosci. Biobehav. Rev. 72, 310–324. https://doi.org/10.1016/j.neubiorev.2016.11.012 (2017).

    CAS 
    Article 
    PubMed 

    Google Scholar     

  • 71.

    Sidik, K. & Jonkman, J. N. A comparison of heterogeneity variance estimators in combining results of studies. Stat. Med. 26, 1964–1981 (2007).

    MathSciNet 
    Article 

    Google Scholar